25-Hydroxyvitamin D Threshold for the Effects of Vitamin D Supplements on Bone Density:Secondary Analysis of a Randomized Controlled Trial

Macdonald, Helen M, Reid, Ian R, Gamble, Gregory D, Fraser, William D, Tang, Jonathan C and Wood, Adrian D (2018) 25-Hydroxyvitamin D Threshold for the Effects of Vitamin D Supplements on Bone Density:Secondary Analysis of a Randomized Controlled Trial. Journal of Bone and Mineral Research, 33 (8). pp. 1464-1469. ISSN 0884-0431

[img] PDF (Accepted manuscript) - Submitted Version
Restricted to Repository staff only until 31 December 2099.

Download (517kB) | Request a copy
[img]
Preview
PDF (Accepted manuscript) - Submitted Version
Available under License Creative Commons Attribution Non-commercial.

Download (851kB) | Preview

Abstract

Most trials of vitamin D supplementation have shown no benefits on bone density (BMD), though severe vitamin D deficiency causes osteomalacia which is associated with profound BMD deficits. Recently, the ViDA-BMD study from New Zealand demonstrated a threshold of baseline 25-hydroxyvitamin D (30 nmol/L) below which vitamin D supplementation did benefit BMD. We have now re-examined data from a similar trial in Aberdeen to determine whether a baseline 25-hydroxyvitamin D threshold of 30 nmol/L is also observed in that database. The Aberdeen study recruited 305 postmenopausal women in late winter and randomized them to receive placebo, vitamin D 400 IU/day or vitamin D 1000 IU/day over one year. As previously reported, BMD loss at the hip was reduced by vitamin D 1000 IU/day only, and there was no significant treatment effect of either dose at the lumbar spine. In the present analysis, when the trial participants were grouped according to whether their baseline 25-hydroxyvitamin D was ≤30 nmol/L or above this threshold, significant treatment effects were apparent at both the spine and hip in those with baseline 25-hydroxyvitamin D ≤30 nmol/L, but no significant effects were apparent in those with baseline 25-hydroxyvitamin D above this level. There was evidence of a similar threshold for effects on parathyroid hormone, but no groups showed changes in bone turnover markers during the study. It is concluded that vitamin D supplements only increase bone density in adults with nadir 25-hydroxyvitamin D ≤30 nmol/L. This moves us further towards a trial-based definition of vitamin D deficiency in adults with adequate calcium intakes, and suggests that supplement use should be targeted accordingly. Future trials of vitamin D supplementation should focus on individuals with 25-hydroxyvitamin D concentrations in this range.

Item Type: Article
Uncontrolled Keywords: vitamin d,vitamin d metabolites,24,25-dihydroxyvitamin d,osteoporosis,dxa,nutrition,biochemical markers of bone turnover,pth
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: Pure Connector
Date Deposited: 16 Apr 2018 08:30
Last Modified: 18 Mar 2020 01:16
URI: https://ueaeprints.uea.ac.uk/id/eprint/66766
DOI: 10.1002/jbmr.3442

Actions (login required)

View Item View Item